News & Events

News &
Events

Tarsier Pharma to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024

August 15, 2024

Tarsier Pharma, Ltd., a clinical stage biopharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat immune-mediated blinding diseases in the front and back of the eye, is excited to announce its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024.

Dr. Daphne Haim-Langford, CEO and Chairperson of Tarsier Pharma, will present a corporate update, sharing the latest developments and future plans for the company followed by her participation at the panel Novel Approaches for Front-of-the-Eye Indications which will be led by Mr. Yi Chen Managing Director, Equity Research @ H.C. Wainwright & Co.

Additionally, Dr. Haim-Langford and Emilee Fulcher, VP of Clinical Affairs, will be available for one-on-one meetings with investors, providing a unique opportunity for in-depth discussions with company executives. Institutional investors interested in scheduling a meeting are encouraged to contact their H.C. Wainwright representative or register for the event here.

About Tarsier Pharma

Tarsier® Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The Dazdotuftide (TRS) Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections.

Contact:

Investor Relations Tarsier Pharma

[email protected]

Scroll to Top